双歧杆菌三联活菌胶囊联合莫沙必利治疗功能性消化不良的疗效及预防复发作用

目的探讨双歧杆菌三联活菌胶囊联合莫沙必利治疗功能性消化不良（FD）的疗效及预防复发作用。方法选取FD患者80例,随机分为观察组和对照组。两组患者予以莫沙必利片5 mg,3次/d,连用8周。观察组患者加用双歧杆菌三联活菌胶囊420 mg,3次/d,连用8周。对照组患者除不使用双歧杆菌三联活菌胶囊外余治疗同观察组。观察两组患者治疗后的临床疗效及安全性,并比较治疗后随访6个月内的复发率。结果治疗8周后,观察组患者临床总有效率（95.0%）明显高于对照组（75.0%）（χ2=4.11,P〈0.05）;观察组和对照组治疗期间出现不良反应2例和4例,症状较轻,两组不良反应发生率比较差异无统计学意义（χ2=0.18,P〉0.05）。治疗后随访6个月,观察组和对照组分别复发5例（12.5%）和13例（32.5%）,观察组患者的复发率明显低于对照组（χ2=4.59,P〈0.05）。结论双歧杆菌三联活菌胶囊联合莫沙必利治疗FD的疗效肯定,安全性较好,并能明显降低其复发率,具有预防病情复发作用。

Curative and preventive effects of Bifid Triple Viable Capsules combined with Mosapride on functional dyspepsia

Objective To discuss the curative and preventive effects of Bifid Triple Viable Capsules combined with Mosapride on functional dyspepsia （FD）. Methods 80 cases of patients with FD were selected and divided into observation group and control group at random. Both groups were given 5 mg of Mosapride tablets, three times a day for 8 weeks. The patients in observation group were additionally given 420 mg of Bifid Triple Viable Capsules, three times a day for 8 weeks. The clinical curative effect and safety in the two groups were observed, and reoccurrence rate within 6 months＇ follow-up after treatment was compared. Results The total clinical efficiency in observation group was 95.0% , much higher than that in control group （75.0%） （X2 = 4. 11, P 〈 0. 05 ）. 2 and 4 cases of adverse effects appeared in observation group and control group respectively, with mild symptom, and the difference between the occurrence rates of the two groups was not significant （X2 = 0.18, P 〉0.05）. 5 and 13 cases of reoccurrence appeared in observation group （ 12.5% ） and control group （ 32.5% ） respectively within 6 months＇ follow-up, with the reoccurrence rate in observation group much lower than that in control group （X2 = 4.59, P 〈 0.05 ）. Conclusion Bifid Triple Viable Capsules combined with Mosapride has confirmative curative effect on FD with high safety, which can obviously reduce the reoccurrence rate and prevent the reoccurrence.